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A B S T R A C T
Non-tuberculous mycobacteria can cause catheter associated blood stream infections. The causative
agents are generally rapid growers that belong to the Mycobacterium fortuitum and Mycobacterium
mucogenicum groups. A 65 year hospitalized patient with temporary central venous catheter who
developed Mycobacterium smegmatis bacteremia. Bacteremia cleared after removal of the catheter.
Patient was treated initially with 4 weeks of intravenous amikacin, intravenous meropenem, oral
doxycycline and oral ethambutol and then deescalated to oral doxycycline and oral ciprofloxacin for 8
weeks. He improved clinically and remained stable. A literature search identified total of 22 articles that
reported 47 unique cases of Mycobacterium smegmatis infection. To our knowledge, this is the first case
of Mycobacterium smegmatis central venous catheter associated bacteremia in an immunocompetent
host.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Non-tuberculous mycobacterial (NTM) human infections are
gaining clinical recognition due to modern molecular techniques.
NTM can cause skin and soft tissue infection, lymphadenitis,
pulmonary infection, bone and joint infection, catheter related
bacteremia and disseminated infection. Sporadic cases of health
care associated infections are reported. These cases include
infections due to peritoneal catheter; intravenous indwelling
catheters, injection related abscesses, surgical site wounds and
infections post plastic surgery procedures [1].
NTMs are classified, in part, classified based on their growth
rate. Rapidly growing mycobacteria (RGM) produce mature
growth on media plates within 7 days. There are currently six
groups based on pigmentation and genetic relatedness. One group
within RGM is the Mycobacterium smegmatis group consisting of
two late pigmenting species: Mycobacterium smegmatis and
Mycobacterium goodii. Mycobacterium smegmatis is resistant to
anti tuberculous agents except for ethambutol. Generally, it has an
erm gene, which induces macrolide resistance. Monotherapy with
quinolones is avoided due to high risk of mutational resistance to
these agents [1].
Currently, catheter related infections are the most common
health care associated NTM infections encountered. These Infections* Corresponding author at: 545 Barnhill Drive EH 421, Indianapolis, IN, 46202,
United States.
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also occur with peritoneal or shunt catheters. The causative RGMs
usually belong to the Mycobacterium fortuitum and Mycobacterium
mucogenicum groups. Treatment involves removal of the catheter
and long-term antibiotics for 6–12 weeks [1]. We present the first
case of Mycobacterium smegmatis catheter associated bloodstream
infection in an immunocompetent patient.
Case report
A 64 year old Caucasian male with recent history of constrictive
pericarditis and 4.7 cm ascending aortic aneurysm was admitted to
the hospital for an elective surgery. He underwent repair of his
ascending aortic aneurysm and pericardiectomy on day 1 of
admission. During his hospital stay, he had a cardiac arrest with
ventricular fibrillation and underwent pacemaker placement (day
7). He also developed acute kidney injury and underwent tunneled
central venous catheter (CVC) placement for hemodialysis (day 10).
He was transferred to the intensive care unit (ICU) with
hypotension and fever, and blood cultures were drawn (day 20).
Microbiology laboratory reported blood cultures positive for RGM,
possibly mycobacterium smegmatis based on in-house MALDI-TOF
(matrix-assisted laser desorption ionization time-of-flight mass
spectrometry) (day 24). Mycobacterium tuberculosis PCR was
negative. Infectious diseases team was consulted and CVC was
removed per their advice (day 26). Repeat blood cultures drawn on
day 24 and day 26 were reported positive for RGM. The patient was
started on empiric intravenous (IV) amikacin 15 mg/kg every 24 h,
IV meropenem 1 g every 8 h, oral (PO) ethambutol 1200 mg dailyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for Mycobacterium smegmatis (day 28). Post catheter removal, he
improved clinically and his repeat blood cultures obtained on day
28 were negative. Mycobacterium smegmatis isolate was send to
National Jewish Medical Center for susceptibility testing (day 35).
The isolate was resistant to ceftriaxone, cefotaxime and cefepime;
intermediate to clarithromycin, cefoxitin and amoxicillin/clavula-
nate; and susceptible to aminoglycosides, trimethroprim/sulfa-
methaxole, tetracyclines, imipenem, fluoroquinolones, linezolid,Table 1
Mycobacterium smegmatis infections (Literature review).
Study Location Number Risk
factors
Infection
type
Vonmoos
[2]
1986
Switzerland 1 Laryngeal cancer Oil
applied to tracheoma
PNA 
Wallace [3]
1998
USA (18] &
Australia
[4]
21 Surgery, trauma,
catheter
Cardiac surg site,
lymphadenitis, OM, IE,
PNA, SSTI
Plaus [4]
1991
USA 2 veterinary grade
steroid injection
SSTI 
Roger [5]
1991
France 1 trauma
Puncture injury to
ankle while
gardening
SSTI 
Newton [6]
1993
USA 2 MVA SSTI 
Lin [7]
1994
China 1 s/p keratotomy Corneal ulcer 
Cox [8]
1994
USA 1 Mineral oil for
constipation
PNA 
Kumar [9]
1995
India 1 Term infant PNA 
Pierre-
Audigier
[10]
1997
France 1 Interferon gamma
deficiency
Disseminated 
Pennekamp
[11]
1997
1 facelift SSTI 
Skiest [12]
1998
USA 1 catheter CVC BSI 
Schreiber
[13]
2001
Germany 1 Gastrectomy,
splenectomy
PNA 
Ergan [14]
2004
Turkey 1 smoker PNA 
Eid [15]
2007
USA 1 Knee prosthesis PJI 
Chang [16]
2009
Taiwan 3 CVC
IC
CVC BSI 
Corliss [17]
2009
USA 1 none SSTI 
Redelman-
Sidi [18]
2010
USA 2 chemo 1 BSI
1 SSTI
Driks [19]
2011
USA 1 gastrectomy PNA 
Jiang [20]
2011
USA 1 PD peritonitis 
Zimba [21]
2011
USA 1 Lumbar spine
hardware
Vertebral OM 
Shimizu
[22]
2012
1 trauma SSTI 
Saffo [23]
2016
USA 1 Stitch abscess PJI 
Abbreviations: PNA (pneumonia); NA (not available); OM (osteomyelitis); IE (infectious en
catheter); I&D (incision and drainage); abx (antibiotic); doxy (doxycycline); TMP/S
(ciprofloxacin); MVA (motor vehicle accident); f/u (follow up); BSI (blood stream infection
(meropenem); IC (immunocompromised); chemo (chemotherapy); PD (peritoneal dialand clofazamine based on RPOB (β subunit of bacterial RNA
polymerase) gene sequencing (day 48). The patient received 28
days of empiric IV amikacin 15 mg/kg every 24 h, IV meropenem 1 g
every 8 h, PO ethambutol 1200 mg daily and PO doxycycline
100 mg daily and once susceptibilities were available, he was
deescalated to PO doxycycline 100 mg daily and PO ciprofloxacin
500 mg twice a day for 8 weeks. Patient was followed at the
infectious diseases outpatient clinic at the end of treatment and
was still clinically stable by week 12.Bacteremia Treatment Outcome
no NA Resolved
Yes (1
patient)
CVC
Most treated with I&D plus combinations of 3 of these
abx: amikacin, cefoxitin, doxy, TMP/SMX, tobra
20
Resolved,
1 Death
No Erythromycin + amikacin x 2wks f/u cipro x 6 wks
plus I&D
Resolved
No Cefoxitin, doxy, TMP/SMX plus I&D Resolved
No 1) cefoxitin + amikacin f/u TMP/SMX x8 wks plus I&D
2) doxy + cipro
Resolved
No Amikacin + kanamycin f/u amikacin + ofloxacin optic Resolved
No Resolved
No NA Death
Yes Streptomycin+
sulfonamides + ofloxacin
Death
No Cipro + doxy+
amikacin
I&D
Resolved
Yes CVC removal, doxy + cipro Resolved
No Rifabutin + ETA + claritho + ofloxacin Resolved
No Doxy + cipro x 3 mo Resolved
No Doxy + amikacin x 2 wks f/u cipro + TMP/SMX
x16wks; MRP + Cipro x4 wks & post implantation
cipro x 6 wks
Resolved
Yes NA Resolved
No Cipro + Doxy x 10 wks
I&D x2
Resolved
1 yes
1 No
NA Resolved
No Doxy + cipro f/u TMP/SMX+
cipro x 14 mo
Resolved
No Cipro + TMP/SMX x 6 mo Resolved
No Amikacin + ETA + TMP/SMX + clarithro
x 12 wks plus I&D but
Retained hardware
Resolved
No cefazolin x 5 days Resolved
No Levo + amp/sulbactam, removal of hardware f/u
doxy + levo x 10 months
Resolved
docarditis); SSTI (skin and soft tissue infection); surg (surgery), CVC (central venous
MX (trimethoprim/sulfamethoxazole); tobra (tobramycin); wks (weeks); cipro
); ETA (ethambutol); clarithro (clarithromycin); PJI (prosthetic joint infection); MRP
ysis); levo (levofloxacin).
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The PubMed database and Google scholar were used to search
the medical literature to identify all reported cases of Mycobacte-
rium smegmatis infections. A secondary search was performed
using references in the articles identified in the initial search. We
identified total of 22 articles that reported 47 unique cases of
Mycobacterium smegmatis infection (Table 1).
Discussion
Literature review of all reported cases of Mycobacterium
smegmatis revealed 21 cases of skin and soft tissue infections
[3–6,11,17,18,22], 8 cases each of pneumonia [2,3,8,9,13,14,19], and
joint infections [3,15,21,23], 1 case each of endocarditis [3], corneal
ulcer [7] and disseminated infection (10) and 6 cases of catheter-
associated bacteremia [3,12,16,18], (Table 1). Various rapidly
growing mycobacteria (RGM) species has been associated with
catheter-associated infections. These infections are seen with long-
term central venous catheter, peritoneal or shunt catheters. Most
common causative species are members of the Mycobacterium
fortuitum and Mycobacterium mucogenicum groups. These infec-
tions generally present with fever, local catheter site drainage, lung
infiltrates or bacteremia [1]. Mycobacterium smegmatis bacteremia
has been reported in CVC associated infections in immunocom-
promised hosts. Wallace [3], Skiest [12], and Redelman-Sidi [18]
have described one case each in cancer patients and Chang [16]
described 3 cases of Mycobacterium smegmatis catheter-associated
bacteremia in immunocompromised patients.
We present the first case of Mycobacterium smegmatis central
venous catheter-associated bacteremia in an immunocompetent
host. The patient developed bacteremia 10 days post CVC
placement. Blood cultures were obtained due to hypotension
and fever. He had no catheter site inflammation or drainage. No
abnormalities were seen on chest x-ray. Infection control was
notified and they labeled it as an isolated case of infection. Catheter
was removed for source control as bacteremia can relapse in
patients with delayed catheter removal. The catheter tip was send
for culture, which did grow Mycobacterium smegmatis. Bacteremia
cleared post catheter removal. Initially, the patient was empirically
treated with amikacin, meropenem, ethambutol and doxycycline.
The empiric antimicrobial agents were chosen based on known
Mycobacterium smegmatis in-vitro susceptibility to sulfonamides,
doxycycline, imipenem and amikacin. Cephalosporins and macro-
lides were avoided due to resistance. Our patient’s isolate was send
to National Jewish Medical Center for susceptibility testing and
antimicrobial agents were later narrowed to doxycycline and
ciprofloxacin based on these results.
Mycobacterium smegmatis can rarely cause catheter-associated
bacteremia in any patient with an indwelling catheter regardless of
their immune status so it should be considered as part of the
differential. Management includes source control, susceptibility
testing, and appropriate antimicrobial agents.
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